Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.M Pharmaceutical will engage a participant of the Depository Trust Company (DTC) to request that its securities become eligible for depository services.
Subscribe to our email newsletter
DTC Eligibility allows for a Company’s securities to be traded electronically between brokerage accounts in the U.S.
M Pharmaceutical CEO Matthew Lehman said: "DTC Eligibility is a significant step toward improving the liquidity of our stock in the U.S. market. This will allow for electronic trading of M Pharma’s securities via the OTCQB which, as of this time, is not possible."
Formed in early 2015, M Pharmaceutical is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications.
The Company acquired the exclusive rights to three technologies invented by Dr. Martin Mintchev at the University of Calgary: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.